Patients with coronary heart disease who used statins were at a decreased risk of depression; whether there is a cause-and effect relationship, however, merits further research, according to a study published online February 21 in The Journal of Clinical Psychiatry.
Apixiban (Eliquis) is an orally active factor Xa inhibitor. Its manufacturers are seeking FDA approval to market apixaban to reduce risk of stroke and systemic embolism in patients with nonvalvular AF (NVAF).
New formulation: FDA approved Exenatide extended-release, a once-weekly treatment (along with diet and exercise) to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings
Recent FDA Approvals (through April 2012) related to (Johnson & Johnson, AstraZeneca, Affymax, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Avioq, Hope Pharmaceuticals, Novo Nordisk, Avid Radiopharmaceuticals)
A report for the American College of Cardiology's Scientific Session & Expo
Are drug-price guarantees here to stay?
The face of pharmacy benefit management continues to change in the wake of the $29.1 billion merger.
Private payers have the most experience with managing risk, but each stakeholder must achieve a perfect balance of risk and reward.
In spite of a drug pipeline that produced 34 new drugs moving to the market, U.S. spending on prescription drugs rose a negligible amount in 2011, according to a report from IMS Institute.
The "arms race" among hospitals to be more competitive has led to the trend of hospitals expanding into targeted geographic markets to capture well-insured patients.
Your members might be skipping out on their responsibilities.
Stakeholders must find common ground, according to a new survey on the subject by PricewaterhouseCoopers.
Proven programs lead to better drug compliance among diabetic members.
Uncertainty remains in funding high-risk pools.
The concept of rewarding quality improvement is widely embraced, but implementation is far from perfect.
Rise of payers buying providers leads to complex legal issues.
In this new era of business-to-consumer marketing, small plans might have an advantage.
Interoperability rules go into effect soon.
No one is optimistic that Congress will make changes in benefits or outlays needed to improve the financial picture.
An increase in smartphone and e-reader use among older Americans has propelled the launch of a new health literacy initiative
Not everyone responds to incentives, so keep reminding your members to engage
Basic Health Program could broaden available coverage options for the poor.
The National Association of Boards of Pharmacy, the Accreditation Council for Pharmacy Education (ACPE), and ACPE providers have teamed up to create the CPE Monitor. This new system will allow for the electronic transmission of continuing pharmacy education data.
FDA has issued a safety alert, warning patients, caregivers, and healthcare professionals about the dangers of accidental exposure to and improper storage and disposal of fentanyl patches.
As many as 80% of patients who are candidates for preventive treatments for migraine headaches could be helped by these treatments, the author of new guidelines issued by the American Academy of Neurology told Formulary.
Twice-daily dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim) was shown to be associated with lower rates of fatal and traumatic intracranial hemorrhage compared with warfarin, according to the results of a retrospective subanalysis published online, April 5, in Stroke, the Journal of the American Heart Association.
More than 75% of the nation?s opinion leaders believe that the best way to control healthcare costs is through discovering innovative ways to deliver services, according to the new NEHI Innovation Barometer survey.
Novartis has agreed with FDA to update US prescribing information on fingolimod (Gilenya) to include updated patient selection parameters based on certain cardiovascular considerations to aid in the identification of candidates for Gilenya.
FDA has issued a Drug Safety Communication (April 20) warning of possible risks when using blood pressure medicines containing aliskiren with angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with diabetes or kidney (renal) impairment. These drug combinations are contraindicated in patients with diabetes.
Guidelines for managing elevated blood glucose levels in people with type 2 diabetes mellitus, developed jointly by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), are being published concurrently in the ADA?s journal, April 19 online edition of Diabetes Care and in EASD?s journal, Diabetologia.